Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription 09.09.2024 1 AJR Am J Roentgenol 1 BMC Cancer 1 BMC Urol 2 Br J Cancer 1 Cancer Lett 1 Eur J Radiol 4 Eur Urol 1 Int J Cancer 4 Int J Urol 1 J Clin Oncol 4 J Nucl Med 1 J Urol 2 Nat Rev Urol 1 PLoS One 3 Prostate 1 Urol Int

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. TAN N, Pollock JR, Margolis DJA, Padhani AR, et al
   Management of Patients With a Negative Multiparametric Prostate MRI Examination: AJR Expert Panel Narrative Review.
   AJR Am J Roentgenol. 2023 Oct 25. doi: 10.2214/AJR.23.29969.
   PubMed         Abstract available
   
   

   
   BMC Cancer

2. SHEN C, Zhu X, Chen Z, Zhang W, et al
   Nomogram predicting early urinary incontinence after radical prostatectomy.
   BMC Cancer. 2024;24:1095.
   PubMed         Abstract available
   
   

   
   BMC Urol

3. VAN CALSTER C, Everaerts W, Geraerts I, De Groef A, et al
   Characteristics of lymphoedema, in particular midline lymphoedema, after treatment for prostate cancer: a retrospective study.
   BMC Urol. 2024;24:192.
   PubMed         Abstract available
   
   

   
   Br J Cancer

4. WANG T, Wang X, Ding G, Liu H, et al
   Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.
   Br J Cancer. 2024 Sep 2. doi: 10.1038/s41416-024-02823.
   PubMed         Abstract available
   
   
5. NTURUBIKA BD, Guardia CM, Gershlick DC, Logan JM, et al
   Altered expression of vesicular trafficking machinery in prostate cancer affects lysosomal dynamics and provides insight into the underlying biology and disease progression.
   Br J Cancer. 2024 Aug 31. doi: 10.1038/s41416-024-02829.
   PubMed         Abstract available
   
   

   
   Cancer Lett

6. HE Q, Zhang Y, Li W, Chen S, et al
   Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy.
   Cancer Lett. 2024;602:217214.
   PubMed         Abstract available
   
   

   
   Eur J Radiol

7. YADAV D, Dutruel SP, O'Dwyer E, Ricaurte-Fajardo A, et al
   PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer.
   Eur J Radiol. 2024;180:111711.
   PubMed         Abstract available
   
   

   
   Eur Urol

8. NAIR SS, Muhammad H, Jain P, Xie C, et al
   A Novel Artificial Intelligence-powered Tool for Precise Risk Stratification of Prostate Cancer Progression in Patients with Clinical Intermediate Risk.
   Eur Urol. 2024 Sep 3:S0302-2838(24)02496-5. doi: 10.1016/j.eururo.2024.
   PubMed        
   
   
9. KASIVISVANATHAN V, Wai-Shun Chan V, Clement KD, Levis B, et al
   VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Detection of Prostate Cancer.
   Eur Urol. 2024 Sep 3:S0302-2838(24)02559-4. doi: 10.1016/j.eururo.2024.
   PubMed         Abstract available
   
   
10. VYNCKIER P, Annemans L, Roobol M
    Reply to Andres Gutierrez, Julio Cesar Boada, and Sebastian Pena's Letter to the Editor re: Pieter Vynckier, Lieven Annemans, Sarah Raes, et al. Systematic Review on the Cost-effectiveness of Prostate Cancer Screening in Europe. Eur Urol. In press. ht
    Eur Urol. 2024 Sep 2:S0302-2838(24)02566-1. doi: 10.1016/j.eururo.2024.
    PubMed        
    
    
11. GUTIERREZ A, Boada JC, Pena S
    Re: Pieter Vynckier, Lieven Annemans, Sarah Raes, et al. Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.04.036.
    Eur Urol. 2024 Aug 30:S0302-2838(24)02565-X. doi: 10.1016/j.eururo.2024.
    PubMed        
    
    

    
    Int J Cancer

12. MOGHUL M, Tran A, Croft F, Kinsella N, et al
    The Man Van: A pilot study of using mobile targeted case-finding to address health inequalities in prostate cancer.
    Int J Cancer. 2024 Sep 4. doi: 10.1002/ijc.35169.
    PubMed         Abstract available
    
    

    
    Int J Urol

13. COLAKOGLU Y, Eksi M, Ozlu DN, Simsek A, et al
    Comparison of oncological and functional results of robotic and open perineal radical prostatectomy.
    Int J Urol. 2024;31:994-1000.
    PubMed         Abstract available
    
    
14. MORITA M, Hiramatsu A, Nishimura K, Yanagida W, et al
    Radiation proctitis after iodine-125 low-dose-rate prostate brachytherapy utilizing SpaceOAR hydrogel.
    Int J Urol. 2024;31:1001-1008.
    PubMed         Abstract available
    
    
15. SAITO K, Kohada Y, Hieda K, Shikuma H, et al
    Preoperative high serum total testosterone levels predict preserved postoperative sexual function in patients after nerve-sparing robot-assisted radical prostatectomy.
    Int J Urol. 2024 Jun 7. doi: 10.1111/iju.15511.
    PubMed         Abstract available
    
    
16. KATO T, Tohi Y, Okazoe H, Taoka R, et al
    How widespread is active surveillance of early-stage prostate cancer in Japan? Multicenter questionnaire survey on the status of active surveillance of early-stage prostate cancer in Japan.
    Int J Urol. 2024 Sep 4. doi: 10.1111/iju.15573.
    PubMed        
    
    

    
    J Clin Oncol

17. TOMBAL B, Giannarini G
    Systemic Treatment for Biochemical Recurrence of Localized Prostate Cancer: Do Not EMBARK on When, If the Answer Is How.
    J Clin Oncol. 2024 Sep 6:JCO2401134. doi: 10.1200/JCO.24.01134.
    PubMed        
    
    

    
    J Nucl Med

18. BAUCKNEHT M, D'Amico F, Albano D, Balma M, et al
    Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [(18)F]PSMA-1007 PET/CT.
    J Nucl Med. 2024 Sep 5:jnumed.124.267751. doi: 10.2967/jnumed.124.267751.
    PubMed         Abstract available
    
    
19. YADAV S, Lowery B, Tuchayi AM, Jiang F, et al
    Impact of Posttreatment SPECT/CT on Patient Management During (177)Lu-PSMA-617 Radiopharmaceutical Therapy.
    J Nucl Med. 2024 Aug 8:jnumed.124.267955. doi: 10.2967/jnumed.124.267955.
    PubMed         Abstract available
    
    
20. POSCHENRIEDER A, Taleska J, Schaetz L
    (177)Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening?
    J Nucl Med. 2024;65:1340-1342.
    PubMed        
    
    
21. BELGE BILGIN G, Burkett BJ, Bilgin C, Orme JJ, et al
    Neurologic Symptoms After (177)Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience.
    J Nucl Med. 2024;65:1402-1408.
    PubMed         Abstract available
    
    

    
    J Urol

22. SHORE ND, De Giorgi U, Freedland SJ
    Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK.
    J Urol. 2024 Sep 3:101097JU0000000000004228. doi: 10.1097/JU.0000000000004228.
    PubMed        
    
    

    
    Nat Rev Urol

23. MASONE MC
    Utility of PSA screening in transgender women receiving oestrogens.
    Nat Rev Urol. 2024;21:518.
    PubMed        
    
    
24. KHANNA R, Martinez AG, Raison N, Ourselin S, et al
    Artificial intelligence in the management of prostate cancer.
    Nat Rev Urol. 2024 Sep 4. doi: 10.1038/s41585-024-00938.
    PubMed        
    
    

    
    PLoS One

25. LAI GS, Chen CS, Cheng JC, Li JR, et al
    Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients.
    PLoS One. 2024;19:e0309941.
    PubMed         Abstract available
    
    

    
    Prostate

26. MATRONE F, Del Ben F, Montico M, Muraro E, et al
    Prognostic value of circulating tumor cells in oligorecurrent hormone-sensitive prostate cancer patients undergoing stereotactic body radiation therapy.
    Prostate. 2024 Sep 6. doi: 10.1002/pros.24787.
    PubMed         Abstract available
    
    
27. FALKENBACH F, Ahmad-Sterkau F, Kachanov M, Beyersdorff D, et al
    Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasound.
    Prostate. 2024 Sep 1. doi: 10.1002/pros.24785.
    PubMed         Abstract available
    
    
28. LU S, Lamba M, Wang J, Dong Z, et al
    Targeting proliferating cell nuclear antigen enhances ionizing radiation-induced cytotoxicity in prostate cancer cells.
    Prostate. 2024 Sep 1. doi: 10.1002/pros.24786.
    PubMed         Abstract available
    
    

    
    Urol Int

29. OBERNEDER M, Henzler T, Kriegmair M, Vag T, et al
    Prediction of clinically significant prostate cancer using multi parametric MRI, biparametric MRI and clinical parameters.
    Urol Int. 2024 Aug 31. doi: 10.1159/000541152.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.